IceCure Medical
ICCM

$0.6445

0.85%

Market Cap: $31.9M

0

Funds holding %

of 6,710 funds

0

Analysts bullish %

of 3 analysts

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

110% more capital invested

Capital invested by funds: $127K [Q1] → $268K (+$140K) [Q2]

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

67% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 3

17% more funds holding

Funds holding: 12 [Q1] → 14 (+2) [Q2]

0.52% more ownership

Funds ownership: 0.23% [Q1] → 0.75% (+0.52%) [Q2]

See Fund Rankings

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$2.50

288%

upside

Avg. target

$2.67

314%

upside

High target

$3

365%

upside

3 analyst ratings

3 positive

100%

0 neutral

0%

0 negative

0%

HC Wainwright & Co. Yi Chen 36% 1-year accuracy 47 / 129 met price target	288%upside $2.50	Buy Reiterated	12 Sept 2024
HC Wainwright & Co. Yi Chen 36% 1-year accuracy 47 / 129 met price target	288%upside $2.50	Buy Maintained	21 Aug 2024
HC Wainwright & Co. Yi Chen 36% 1-year accuracy 47 / 129 met price target	365%upside $3	Buy Reiterated	2 Jul 2024

See Analyst Rankings

Financial journalist opinion

Based on 4 articles about ICCM published over the past 30 days

Study Published in the British Journal of Radiology Demonstrates IceCure's ProSense® is a Safe Procedure with 97.7% Technical Success Rate in Treating Tumors of the Lung, Bone, and Soft Tissues

Liquid nitrogen- (LN2) based ProSense® found to have favorable safety compared to argon-based cryoablation systems, as well as being more cost effective and easier to manage Independent study conducted at the European Institute of Oncology (IEO) demonstrates interventional radiology use cases for ProSense® for indications that are approved in various markets across the world CAESAREA, Israel , Sept. 16, 2024 /PRNewswire/ -- IceCure Medical Ltd.

Study Published in the British Journal of Radiology Demonstrates IceCure's ProSense® is a Safe Procedure with 97.7% Technical Success Rate in Treating Tumors of the Lung, Bone, and Soft Tissues

IceCure Announces FDA Advisory Panel Meeting Date for Marketing Authorization of ProSense® in Early-Stage Low Risk Breast Cancer Scheduled for November 7, 2024

Public forum to evaluate ProSense® cryoablation as a minimally invasive alternative to lumpectomy for an estimated 70,000 women diagnosed in U.S. annually with early-stage low risk breast cancer F DA decision regarding marketing authorization of ProSense® expected by early 2025 CAESAREA, Israel , Sept. 12, 2024 /PRNewswire/ -- IceCure Medical Ltd.

IceCure Announces FDA Advisory Panel Meeting Date for Marketing Authorization of ProSense® in Early-Stage Low Risk Breast Cancer Scheduled for November 7, 2024

IceCure to Meet Institutional Investors at the H.C. Wainwright and Lake Street Capital Markets Conferences

Company presentation to focus on how IceCure's industry-leading ProSense® enables non-surgical treatment of benign and cancerous tumors and upcoming n ear-term regulatory and operating catalysts CAESAREA, Israel , Sept. 4, 2024 /PRNewswire/ -- IceCure Medical Ltd.

IceCure to Meet Institutional Investors at the H.C. Wainwright and Lake Street Capital Markets Conferences

USPTO Grants Notice of Allowance for Additional Patent on IceCure's Novel Cryogenic Pump Technology: Reinforces IceCure's Global IP Leadership in Cryoablation Technologies

Further broadens the uses and applications of IceCure's cryoablation platform into a wide range of technology fields Over 50 patents issued and allowed worldwide for IceCure's platform cryoablation technology CAESAREA, Israel , Aug. 28, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced it has received a Notice of Allowance from the U.S. Patent and Trademark Office ("USPTO") for a continuation application based on the Company's issued patent titled "Cryogen Pump".

USPTO Grants Notice of Allowance for Additional Patent on IceCure's Novel Cryogenic Pump Technology: Reinforces IceCure's Global IP Leadership in Cryoablation Technologies

IceCure Medical Ltd (ICCM) Q2 2024 Earnings Call Transcript

IceCure Medical Ltd (NASDAQ:ICCM ) Q2 2024 Earnings Call Transcript August 20, 2024 10:00 AM ET Company Participants Michael Polyviou - IR Shad Good - VP of North American Sales Ronen Tsimerman - CFO and COO Conference Call Participants Anthony Vendetti - Maxim Group Kemp Dolliver - Brookline Capital Markets Ben Haynor - Lake Street Yi Chen - H.C. Wainwright Operator Good morning, and thank you for standing by.

IceCure Medical Ltd (ICCM) Q2 2024 Earnings Call Transcript

Zacks Investment Research

IceCure Medical Ltd. (ICCM) Reports Q2 Loss, Tops Revenue Estimates

IceCure Medical Ltd. (ICCM) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.07.

IceCure Medical Ltd. (ICCM) Reports Q2 Loss, Tops Revenue Estimates

IceCure Medical Reports 20% Growth in ProSense® System and Probe Sales for the First Half of 2024; Reflects Continued Adoption in the U.S. and Other Global Markets

Near-term regulatory and operating catalysts have potential to accelerate adoption of ProSense® for treatment of early-stage, low risk breast cancer Conference call to be held today at 10:00 am Eastern Time CAESAREA, Israel , Aug. 20, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure," "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today reported financial results as of and for the six months ended June 30, 2024.

IceCure Medical Reports 20% Growth in ProSense® System and Probe Sales for the First Half of 2024; Reflects Continued Adoption in the U.S. and Other Global Markets

IceCure's ProSense® Destroyed 100% of Breast Cancer Tumors in Independent Study of Patients Who Chose Cryoablation Instead of Surgery

After a median follow-up of 16 months, the complete ablation rate in Luminal A and B breast cancer tumors ≤ 25mm was 100% Study concluded that most non-surgical patients with early-stage breast cancer accepted cryoablation when the treatment was offered and that cryoablation is a safe, effective alternative to surgery and well-tolerated as an out-patient procedure CAESAREA, Israel , Aug. 14, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced the publication of an independent study titled "Acceptance and results of cryoablation for the treatment of early breast cancer in non-surgical patients" in the British Journal of Radiology , a publication of the British Institute of Radiology.

IceCure's ProSense® Destroyed 100% of Breast Cancer Tumors in Independent Study of Patients Who Chose Cryoablation Instead of Surgery

IceCure Medical to Report Second Quarter 2024 Financial & Operational Results on August 20, 2024

CAESAREA, Israel , Aug. 13, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, announced today that it will issue a press release with its financial and operational results as of and for the six months ended June 30, 2024 before the Nasdaq Stock Market opens on Tuesday, August 20, 2024.

IceCure Medical to Report Second Quarter 2024 Financial & Operational Results on August 20, 2024

IceCure Announces Positive Data from the Largest Multi-Institutional Study of its Kind: "Cryoablation of Primary Breast Cancer in Patients Ineligible for Clinical Trials"

Investigator initiated independent study included higher risk patients such as those with metastatic disease, large tumors, and comorbidities, as compared to IceCure's ICE3 study which treated early-stage breast cancer patients Recurrence-free rates were 94.7%, 87.8%, and 81.8%, at 1, 2, and 3 years, respectively Study published in American Journal of Roentgenology was conducted at 7 U.S. institutions and led by Principal Investigators Dr. Karim Oueidat and Dr. Robert Ward, both of the Warren Alpert Medical School of Brown University CAESAREA, Israel , Aug. 7, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced the publication of an independent study titled "Cryoablation of Primary Breast Cancer in Patients Ineligible for Clinical Trials: A Multi-institutional Study" in a leading radiology journal, the American Journal of Roentgenology (AJR).

IceCure Announces Positive Data from the Largest Multi-Institutional Study of its Kind: "Cryoablation of Primary Breast Cancer in Patients Ineligible for Clinical Trials"

See News Rankings